NCT06658002 · University of California, San Francisco
Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
(FANCY)
What this study is about
The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with the usual treatment topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
View original scientific description
The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
Interventions
DRUG
Cyclosporine A
Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
OTHER
Placebo Comparator: Placebo
Participants with smear or culture proven fungal keratitis are treated for a minimum of 48 hours with topical natamycin and then randomized in a 1:1:1 ratio to receive either topical Cyclosporine A (CsA) 0.1%, 2% or placebo for 4 weeks. Natamycin is continued until the ulcer has healed.
Primary outcome measures
Best Spectacle Corrected Visual Acuity (BSCVA)
Time frame: 12 weeks
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Smear or culture positive for fungal keratitis, any length.
- Age 18 years.
- Willing to participate in study.
Exclusion criteria
- Co-infection with bacterial or viral keratitis.
- Corneal perforation.
- Requiring therapeutic keratoplasty for fungal keratitis.
- Unwilling or unable to follow up (e.g., living too far from hospital).
- Presenting acuity better than 20/40 = 6/12 = 0.3 Log MAR or worse than 20/400 = 3/60 = +1.3 Log MAR.
- Subjects taking cyclosporine at any concentration on presentation.
- Acuity worse than 20/200 = 6/60 = +1.0 Log MAR in unaffected eye.
- Pregnant women.
- Penetrating Keratoplasty.
- Presents with a 0-7 day history of topical steroid.
Where
- San Francisco, California
Collaborators
Aravind Eye Hospitals, India, Aravind Eye Care System
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Jun 5, 2026 · Source of record for eligibility and locations